ENGNenGene Holdings Inc.
- Earnings Call Transcripts
Morgan Stanley 24th Annual Global Healthcare Conference - ENGENE THERAPEUTICS INC
All right, good morning, everyone, and welcome to the 2026 Morgan Stanley Global Healthcare Conference. I'm Judah Fromer, one of the mid-camp biotech analysts here. We're very excited to have Ron Cooper from NGENE kickin ...
- Analyst Upgrades
Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform
Citizens analyst Silvan Turkcan reiterates enGene Therapeutics from Market Perform to Market Perform. ...
- BusinessWire
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 Pre-Biologics License Application ...
- BusinessWire
enGene to Participate in Upcoming Investor Conferences
enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor ...
- BusinessWire
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on ...
- BusinessWire
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Michael Heffernan assumes the role of Chairman of the Board Dr. Richard Glickman to step down Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026 Initiation of BLA submission for ...
- GlobeNewswire
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral ...
- Analyst Upgrades
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page. ...
- Analyst Upgrades
Morgan Stanley Downgrades enGene Therapeutics to Underweight
Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics from Equal-Weight to Underweight. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics with a Buy and lowers the price target from $6 to $4. ...
- BusinessWire
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First ...
- PR Newswire
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene... ...
- PR Newswire
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene... ...
- PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors... ...
- PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors... ...
- PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. ("Engene" or the "Company") (NASDAQ: ENGN). Such investors... ...
- Analyst Upgrades
Citizens Downgrades enGene Therapeutics to Market Perform
Citizens analyst Silvan Turkcan downgrades enGene Therapeutics from Market Outperform to Market Perform. ...
- Analyst Upgrades
Guggenheim Downgrades enGene Therapeutics to Neutral
Guggenheim analyst Michael Schmidt downgrades enGene Therapeutics from Buy to Neutral. ...
- Analyst Upgrades
Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2
Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics from Overweight to Equal-Weight and lowers the price target from $25 to $2. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics with a Buy and lowers the price target from $25 to $6. ...
- Analyst Upgrades
Piper Sandler Downgrades enGene Therapeutics to Neutral, Lowers Price Target to $4
Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics from Overweight to Neutral and lowers the price target from $7 to $4. ...
- BusinessWire
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
54% complete response (CR) rate at any time; 43% six‑month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse events ...
- Analyst Upgrades
WBB Securities Initiates Coverage On enGene Therapeutics with Buy Rating, Announces Price Target of $21.5
WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics with a Buy rating and announces Price Target of $21.5. ...
- BusinessWire
enGene Announces Name Change to enGene Therapeutics Inc.
Name change reflects transition towards potential commercial organization in 2027 Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026 enGene Therapeutics Inc. (formerly, enGene ...
- PR Newswire
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
USANewsGroup.com News Commentary — The global oncology market is valued at $279.98 billion in 2026 and is on track to reach $748.17 billion by... ...